|drug983||Daclatasvir 60 mg Wiki||1.00|
|drug3164||Sofosbuvir + Daclatasvir 120 mg Wiki||1.00|
|drug3172||Sofusbuvir + Daclastavir 60 mg Wiki||1.00|
|drug982||Daclatasvir 120 mg Wiki||1.00|
|drug2520||Placebo Atazanavir Wiki||1.00|
|drug2532||Placebo Sofusbuvir + Daclatasvir 60 mg Wiki||1.00|
|drug2531||Placebo Sofosbuvir/Daclatasvir 120 Wiki||1.00|
|drug2522||Placebo Daclatasvir 120 Wiki||1.00|
There is one clinical trial.
A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent that would decrease the peak viral load and, consequently, the associated degree of immunopathological damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among patients under treatment for these aforementioned viruses is empirical less common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that patients with COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir.
Description: Change in the slope of the SARS-COV 2 log viral load evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (isolated antiviral).Measure: Phase II first step: Change in area under the curve of SARS-COV 2 viral load Time: days 3, 6 and 9 after randomization
Description: Change in the slope of the SARS-COV 2 log viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (combined antiviral).Measure: Phase II second step: Change in area under the curve of SARS-COV 2 viral load Time: days 3, 6 and 9 after randomization
Description: Number of days without oxygen, non-invasive ventilation/high flow nasal cannula or need for mechanical ventilation in 15 days.Measure: Phase III: Number of free days from respiratory support Time: 15 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports